_edited.png)
DEA Rescheduling Briefs: What Both Sides Actually Argued About Schedule III
- Bud Lords
- 10 hours ago
- 4 min read
The two sides in the fight over marijuana's federal status have now laid their cards on the table. On August 17, 2026, the government and a coalition of opponents filed their final post-hearing briefs with the Drug Enforcement Administration's Office of Administrative Law Judges, and the actual arguments are now public. Here is what each side told the judge, and what it could mean for cannabis consumers across DC, Maryland, and Virginia.
What just happened, in plain terms
The briefs cap an 11-day formal administrative hearing that wrapped in mid-July 2026 and produced a transcript running roughly 2,470 pages. Post-hearing briefs are where each party makes its closing written case. Chief Administrative Law Judge Derek Julius now reviews them, then drafts a recommendation on whether marijuana should be moved from Schedule I of the Controlled Substances Act to Schedule III. According to reporting from Marijuana Moment (August 18, 2026), the briefs were filed on the August 17 deadline.
One thing to keep front of mind: the judge's recommendation is non-binding. The final decision rests with the DEA Administrator. So while these briefs matter enormously, they are a step in the process, not the finish line.
What the government (DEA/DOJ) argued for rescheduling
The proponents of rescheduling, the DEA and the Department of Justice, argued that marijuana no longer belongs in Schedule I, the most restrictive category reserved for substances with no accepted medical use and a high potential for abuse.
Their core points, as reported:
Marijuana has a currently accepted medical use (often abbreviated CAMU). The government pointed to roughly 30,000 practitioners treating an estimated 6 million patients across 43 jurisdictions with medical cannabis programs.
It has an accepted level of safety under medical supervision.
A new two-part test for evaluating accepted medical use, authorized by the DOJ Office of Legal Counsel, is the appropriate standard, rather than the older "five-part test" the DEA historically applied.
In short, the government's position is that the science and the reality of state medical programs have moved past the Schedule I framework, and that Schedule III better reflects marijuana's medical use and safety profile.
What the opponents argued against rescheduling
On the other side stood a coalition that included Smart Approaches to Marijuana (SAM), the National Drug and Alcohol Screening Association (NDASA), the states of Idaho, Indiana, Nebraska, and Louisiana, and several individual experts and advocacy groups.
Their core points, as reported:
Marijuana is a "variable substance" that lacks the "known and reproducible chemistry" a medicine normally requires, so it cannot meet the accepted-medical-use standard.
The two-part test was, in their framing, improperly "dreamt up" specifically for this proceeding and should not replace the traditional five-part test.
Rescheduling could undermine workplace drug testing for safety-sensitive roles and complicate law enforcement.
The opponents' brief essentially asks the judge to keep the existing, stricter standard and to conclude that marijuana still fits Schedule I.
A procedural twist: the transcript correction order
On August 20, 2026, Judge Julius issued a 13-page order directing dozens of technical and substantive corrections to the hearing transcript. A corrected transcript is expected to be released publicly around August 26, 2026. It is a housekeeping step, but a meaningful one: the official record has to be accurate before the judge builds a recommendation on top of it.
What happens next
From here, Judge Julius drafts a recommendation. That recommendation then goes to the DEA Administrator, Terry Cole, who holds final decision-making authority. Critically, there is no statutory deadline for the final call, and observers generally expect a decision no earlier than late 2026. We walked through the full sequence in our companion explainer on what happens next in the rescheduling process.
It is also worth separating two tracks that often get blurred together. An April 2026 Final Order already moved FDA-approved cannabis products and state-licensed medical cannabis to Schedule III through an expedited process. That order is the subject of a separate court challenge, the SAM v. DOJ case now before the D.C. Circuit. Adult-use and bulk cannabis, by contrast, remain Schedule I pending this DEA rulemaking.
Why this matters for DMV cannabis consumers
For readers in DC and Maryland's medical programs, and for Virginia consumers watching the market take shape, the stakes are practical. A move to Schedule III would not legalize adult-use marijuana federally, but it would carry real implications, most notably potential relief from the punishing 280E tax rule that currently prevents cannabis businesses from deducting ordinary expenses. Over time, that can influence prices, product availability, and how the regional medical market operates.
Virginia consumers, in particular, are already feeling the effects of a shifting regulatory picture, as we covered when Virginia's 2mg THC cap took effect after a federal judge denied an injunction. Rescheduling is the larger federal backdrop to all of these state-level moves.
The bottom line
Both sides have now made their strongest written case. The government argues marijuana has an accepted medical use and belongs in Schedule III; opponents argue it is too variable to qualify and should stay in Schedule I. The judge's recommendation will land after the corrected transcript, and the DEA Administrator gets the final word, likely late in 2026. As of August 22, 2026, nothing is decided, and we will keep tracking it.
Looking for premium cannabis delivered across DC, Maryland, and Virginia while the policy debate plays out? Browse the Bud Lords menu and order today.
Related Articles
As of August 22, 2026. Sources: Marijuana Moment (Aug 18–19, 2026), The Marijuana Herald (Aug 17, 2026), Morningstar/Accesswire (Aug 21, 2026), and the Federal Register Notice of Hearing (Apr 28, 2026). This is reporting on filed legal arguments, not legal advice; regulatory outcomes remain pending and uncertain.
This article was researched and written with AI assistance by the Bud Lords AI Newsroom.
Comments